〔Abstract〕 Objective To analyze the effect of trexrutin brain protein hydrolysate combined with edaravone in the treatment of acute stroke. Methods A total of 90 cases of acute stroke patients admitted to Shangqiu Hospital of Traditional Chinese Medicine from December 2020 to December 2021 were retrospectivety analyzed and divided into a control group and an observation group according to different treatment plans, with 45 cases in each group. The control group was given edaravone treatment, and the observation group was given trixrutin brain protein hydrolysate combined with edaravone treatment. The clinical efficacy, coagulation function, quality of life, occurrence and recurrence of adverse reactions were compared between the two groups. Results The treatment effect of observation group was better than that in the control group, and the difference was statistically significant (Z = 0.263, P < 0.05). After treatment, platelet count in the two groups were increased to varying degrees, while the levels of fibrinogen and D-dimer were decreased to varying degrees. After treatment, platelet count in the observation group was higher than that in the control group, while the levels of fibrinogen and D-dimer were lower than those in the control group, with statistical significances (P < 0.05). After treatment, the quality of life in the observation group was better than that in the control group, and the difference was statistically significant (Z = 0.26, P < 0.05). The incidence of adverse reactions in the observation group was 8.89%, lower than 13.33% in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in recurrence rate between the two groups (P > 0.05). Conclusion Trixrutin brain protein hydrolysate combined with edaravone is effective in the treatment of acute stroke, which has significant effect on improving clinical symptoms of patients, improving quality of life of patients, and reducing adverse reactions.